REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. for alleged misleading statements and failure to disclose critical information regarding its product Eylea during the Class Period from November 2, 2023, to October 30, 2024 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Regeneron made false statements and failed to disclose that it paid credit card fees to distributors to prevent them from charging Eylea customers more for credit card purchases [5]. - These undisclosed payments allegedly subsidized customer prices, leading to a price concession that lowered Eylea's selling price, which misled investors about the actual sales performance of Eylea [5]. - The lawsuit also alleges that Regeneron overstated the Average Sales Price (ASP) reported to federal agencies, violating the False Claims Act, and that positive statements about the company's business were materially misleading [5]. Group 2: Participation Information - Investors who purchased Regeneron securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].